Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Interventions

pembrolizumab 69 Nivolumab 58 Ipilimumab 35 Specimen Handling 32 Magnetic Resonance Spectroscopy 25 Cyclophosphamide 22 Biopsy 18 cemiplimab 14 fludarabine 13 relatlimab 11 binimetinib 11 Opdualag 11 trametinib 10 fludarabine phosphate 10 Radiosurgery 10 CTLA-4 Antigen 10 avelumab 9 lifileucel 8 dabrafenib 8 Radiotherapy 8 atezolizumab 7 aldesleukin 7 Paclitaxel 7 Blood Specimen Collection 7 encorafenib 6 X-Rays 6 Standard of Care 6 Interleukin-2 6 Immunoglobulin G 6 HhAntag691 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Biological Factors × Dermatologic × 90 days × Clear all

NCT02645149 2026-05-29

Match Mel

Melanoma Institute Australia

Phase 2 Completed

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡